Salud financiera de hoja de balance de Nkarta

Salud financiera controles de criterios 6/6

Nkarta tiene un patrimonio de los accionistas total de $273.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $378.9M y $105.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$248.19m
Patrimonio	US$273.29m
Total pasivo	US$105.60m
Activos totales	US$378.89m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Recent updates

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25

Nkarta: Possible Upside From H1 Update, If Positive

Jan 25

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Jan 16

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Oct 04

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Jun 21

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Mar 06

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($253.1M) de NKTX superan a sus pasivos a corto plazo ($23.3M).

Pasivo a largo plazo: Los activos a corto plazo de NKTX ($253.1M) superan a sus pasivos a largo plazo ($82.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NKTX está libre de deudas.

Reducción de la deuda: NKTX no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NKTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: NKTX dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 35.7% cada año.

Salud financiera de hoja de balance de Nkarta

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Recent updates

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New 90-day high: US$71.96

New 90-day high: US$35.74

New 90-day high: US$35.43

Nkarta Announces Treatment of First Patient in First-In-Human Clinical Trial of Engineered Nkg2d-Based Nk Cell Cancer Immunotherapy Nkx101

Nkarta Announces Presentation of Preclinical Data on NKX019

Nkarta, Inc. Announces Executive Changes

First half earnings released

Nkarta, Inc. has completed an IPO in the amount of $252 million.

Análisis de la situación financiera